effortil perlongets
boehringer ingelheim (pty) ltd - etilefrine hydrochloride - capsule - 25 mg etilefrine hydrochloride
effortil injection 10mg (エホチール注10mg)
sanofi k.k. - etilefrine hydrochloride - injection
capecitabine accord 150mg film-coated tablets tablets film-coated
pharmacare premium limited - capecitabine - tablets film-coated - 150mg
capecitabine accord 300mg film-coated tablets tablets film-coated
pharmacare premium limited - capecitabine - tablets film-coated - 300mg
capecitabine accord 300mg film-coated tablets tablets film-coated
pharmacare premium limited - capecitabine - tablets film-coated - 300mg
penedil 2.5 mg extended release tablets
teva pharmaceutical industries ltd, israel - felodipine - tablets extended release - felodipine 2.5 mg - felodipine - felodipine - hypertension. angina pectoris.
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets,cii- dextroamphetami
alvogen inc. - amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e), dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - amphetamine aspartate monohydrate 1.25 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. attention deficit hyperactivity disorder (adhd) a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental eff
nifedi-denk 20 retard tablets prolonged-release
denk pharma gmbh & co. kg - nifedipine - tablets prolonged-release - 20mg
nifedi-denk10 retard tablets prolonged-release
denk pharma gmbh & co. kg - nifedipine - tablets prolonged-release - 10mg